Synaptogenix Announces Collaboration With LSU Health New Orleans For Pre-Clinical Testing Of PUFA Analogs For Spinal Cord Injury
Portfolio Pulse from Benzinga Newsdesk
Synaptogenix has announced a collaboration with LSU Health New Orleans for pre-clinical testing of PUFA analogs for spinal cord injury. Additionally, a new patent has been issued covering the treatment of neurodegenerative diseases. The studies will compare these analogs with Bryostatin in spinal cord injury treatment.
July 18, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Synaptogenix's collaboration with LSU Health New Orleans and the issuance of a new patent for neurodegenerative disease treatment could positively impact the company's stock. The pre-clinical testing of PUFA analogs for spinal cord injury and comparison with Bryostatin may lead to significant advancements in treatment options.
The collaboration with a reputable institution like LSU Health New Orleans and the issuance of a new patent are significant milestones for Synaptogenix. These developments could enhance the company's research capabilities and intellectual property portfolio, potentially leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100